Sonia G. D. V. P.
- Country
- Spain
- Department
- #2029:Hematology
Research Overview
- Safety and Tolerability Assessment of Odronextamab and Cemiplimab in Adult Patients with B-Cell Non-Hodgkin’s Lymphoma
- A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
- A Phase 3 Randomized Study Comparing Odronextamab and Lenalidomide Versus Rituximab and Lenalidomide in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
Data & Insights
Has run more than one trial at 83 of 211 partner sites.
Specializations
B-Cell Lymphoma Expertise
This investigator specializes in treating diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, with particular emphasis on novel therapeutic approaches for relapsed and refractory cases.
- Advanced DLBCL Treatment Strategies
- First-line Therapies for High-risk LBCL
- Marginal Zone Lymphoma Management
Their work involves innovative combinations of immunotherapy and targeted treatments for B-cell lymphomas.
T-Cell Lymphoma Research
The investigator focuses on developing treatments for peripheral T-cell lymphoma (PTCL) and its various subtypes, including novel therapeutic combinations.
- PTCL-NOS Treatment Approaches
- KIR3DL2-Positive PTCL Therapy
- Relapsed/Refractory PTCL Management
Their research encompasses innovative therapeutic strategies for T-cell lymphoma variants.
Therapeutic Innovation
The investigator explores novel therapeutic combinations and targeted therapies across various lymphoma types.
- Antibody-Based Therapies
- Immunotherapy Combinations
- Response-Adapted Treatment Approaches
Their work includes evaluation of emerging treatments and combination strategies for lymphoid malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.